New Delhi. The Indian Pharmaceutical Market recorded healthy growth in May 2026, primarily driven by strong demand in chronic therapy segments such as cardiac, anti-diabetic, and anti-asthmatic medicines. Certain acute-care categories, including calcium supplements and related products, also witnessed notable growth during the month.
Chronic therapies drive market momentum
Traditionally, May is not considered a high-growth period for these therapy segments. However, the increased demand is believed to be influenced by precautionary purchasing patterns, as patients stocked up on regular medications amid concerns over potential supply disruptions and price fluctuations linked to global uncertainties, including developments in the Middle East region.
Seasonal therapies show modest growth
On the other hand, seasonal acute therapy categories such as gastro-intestinal medicines, anti-infectives, cough and cold preparations, and analgesics continued to witness relatively modest growth. These segments are expected to gain momentum with the widespread arrival of the monsoon season across the country.
Semaglutide segment stabilizing
The generic Semaglutide market has started showing signs of stabilization. Following the entry of 31 companies into this segment, the initial phase saw strong stocking demand at distributor and stockist levels. With the market now maturing, volume uptake has moderated, indicating a shift towards more sustainable and balanced growth.
Changing market dynamics
Overall, the pharmaceutical market’s performance in May reflects evolving consumer purchasing behaviour and shifting dynamics across key therapy segments, highlighting both precautionary buying trends and seasonal demand patterns.